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Aim: We investigated the effect of the number of cytosine-adenine (CA) repeats in the ADAMTS9 promoter region on breast cancer
lymphatic metastasis.
Materials and methods: Thirty-one postoperative breast cancer patients were selected and examined retrospectively. The patients were
classified into 2 groups: metastatic or nonmetastatic. Thirty healthy women were selected as the control group, and their peripheral
blood was obtained. Following DNA isolation from the cancer tissue specimens and peripheral blood, the promoter region of the
ADAMTS9 gene was directly sequenced and the number of CA repeats was determined.
Results: The number of CA repeats ranged between 19 and 21 in the control and metastatic groups. However, in the nonmetastatic
group, the number of CA repeats ranged between 17 and 18. This difference in the median number of CA repeats between the control
group and the nonmetastatic group was statistically significant.
Conclusion: A potential relationship may exist between lymphatic metastasis in breast cancer and the number of CA repeats in the
promoter region of the ADAMTS9 gene. Our study indicates a potential association between the number of CA microsatellite repeats
in the promoter region of the ADAMTS9 gene and breast cancer lymphatic metastasis.
Key words: Breast cancer, lymphatic metastasis, ADAMTS9 gene, promoter region, dinucleotide repeats

1. Introduction
Breast cancer is one of the most common malignant
tumors among women, as it constitutes more than 30% of
all cancers in women (1). Environmental factors are known
to play a role in the pathogenesis of breast cancer, and the
genetic factors that contribute to the progression of breast
cancer have also been identified in recent studies (2).
Cancer is a disease initiated by cells that accumulate
inappropriately following the loss of normal cell cycle
regulation and their escape from cellular control systems.
Genetic control mechanisms are involved in every
step of these events (3,4). Most tumors start to spread
microscopically when they reach a volume of 1 mm3
* Correspondence: kdemircan1@gmail.com

(5). However, tumor cells are recognizable by means
of mammography or palpation when they reach larger
volumes.
Metastasis is directed by 2 main principles. The
first is that tumor cells are heterogeneous populations
whose genotypes and phenotypes change over time,
and the second is that the process of metastasis is based
on the metastatic properties of the tumor cells and an
array of events relating to their interactions with the
microenvironment during the course of metastasis. For
example, the amplified synthesis of growth factor receptors,
angiogenic factors, matrix metalloproteinases, and
integrin receptors are key regulators of metastasis. Cancer
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cells that can induce angiogenesis at the metastatic site are
able to invade surrounding blood vessels and enter the
bloodstream to seed additional metastases (2,3). Cancer
cells can also hijack normal cells and use their enzymes to
invade the lymphatic system and blood vessels to initiate
metastasis. In addition, cancer cells promote angiogenesis
and increase the synthesis of invasion precursor enzymes,
such as matrix metalloproteinase-9 (MMP-9), cysteine
and cathepsin proteases,

heparinase, and other matrix
metalloproteinases. Thus, cancer cells enhance their own
proliferation, spreading, and tissue invasion properties.
However, changes in the behavior of tumor cells, due to
their environment and their biological characteristics,
should be considered (6).
ADAMTS (a disintegrin and metalloproteinase with
thrombospondin motifs) gene products were found to
be involved directly in several steps that control gene
expression, mRNA binding, and protein production in both
normal and disease processes (7). ADAMTS proteinases
were also shown to have roles in cell proliferation,
apoptosis, and the direct interaction of cancer cells with
the extracellular matrix.
ADAMTS9 is a member of the ADAMTS gene family
located at 3p14.2 (8), and it is expressed in all embryogenic
tissues and a subset of adult tissues (9). While ADAMTS9
has catalytic activity on the cell surface and performs
its proteolytic activities on other cells through its
thrombospondin repeats, ADAMTS9 also possesses
versicanase and aggrecanase activities in its extracellular
region (7).
With the maximum number of thrombospondin
repeats among the members of the ADAMTS gene family,
ADAMTS9 drew attention due to the long cytosineadenine (CA) microsatellite repeats in its promoter. The
purpose of this study is to determine the effect of the CA
repeat frequency on cancer and metastasis formation.
Microsatellite sequences have been shown to be implicated
in specific gene expression (10). Variations in the length
of CA microsatellite repeats within a promoter region
can change gene expression (11). Thus, CA microsatellite
repeats may be considered as a candidate modulator of
gene expression. Collectively, these repeats might be a
molecular marker in certain conditions. Thus, we aimed
to demonstrate whether the number of CA repeats could
be a useful biomarker in predicting the risk of lymphatic
metastasis of breast cancer. Similar studies were previously
performed with the MMP-9 (12), insulin-like growth
factor 1 (IGF-1) (13), and poly(ADP-ribose) polymerase-1
(PARP-1) (14) genes, which are in the same gene family
or have similar functions as ADAMTS9. To our best
knowledge, no studies have been performed to date to
investigate the potential role of ADAMTS9 gene CA
repeats in breast cancer.
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2. Materials and methods
2.1. Patients
This retrospective study was approved by the Institutional
Review Board of the Fatih University School of Medicine.
Informed consent for the genetic study was obtained
from cancer patients and healthy volunteers. Thirty-one
postoperative breast cancer patients were included in our
retrospective study. After obtaining informed consent,
the medical records of all patients were reviewed. Phase
4 male patients who had palliative resection surgery were
excluded. The patients were grouped as having either
metastatic or nonmetastatic breast cancer. Histological
tissue sections of the tumors from each patient were
annotated according to the pathology records, and the
regions including cancerous tissue from each patient were
labeled under a light microscope. We then conducted our
experiments on tissue samples obtained from paraffin
blocks and corresponding to the regions labeled under
the light microscope. The control group consisted of 30
volunteers who received a diagnosis of any chronic disease
at Fatih University hospital, and they permitted the use of
their peripheral blood samples for DNA isolation.
2.2. Determining the number of CA repeats in the
ADAMTS9 promoter region
Paraffin-embedded tissues were purified using established
methods, and genomic DNA from tissue samples
and peripheral blood leukocytes were isolated using
the PureLinkTM Genomic DNA Mini Kit (Invitrogen,
Carlsbad, CA, USA). The sequences for the forward
and reverse primers used for polymerase chain reaction
(PCR) amplification of the ADAMTS9 promoter region
were 5’ CTTCCTGAGGGCTGGTTAAA 3’ and 5’
CTCCCATCTCTAAACCCCCTG 3’, respectively, and the
expected product length was 180 bp.
PCR amplification was carried out in a 25-µL PCR mix
(QIAGEN, Hilden, Germany) containing 12.5 µL of Taq
PCR master mix, 9.5 µL of dH2O, 2 µL of DNA, and 0.5 µL
of each primer. The samples were denatured at 95 °C for 5
min and then subjected to 35 cycles of amplification at 95
°C for 30 s, annealing at 62 °C for 30 s, and elongation at
72 °C for 1 min, followed by a final extension at 72 °C for
5 min. The amplicons were analyzed in ethidium bromidestained 1.5% agarose gels, which showed single bands of
the expected size in both the patient and control groups.
Next, the amplicons were sequenced in an automated
sequencer (ABI PRISM 310 Genetic Analyzer; Applied
Biosystems, Foster City, CA, USA) according to the
manufacturer’s instructions. Each individual in our study
was classified into 1 of 3 groups: lymphatic metastatic
breast cancer, lymphatic nonmetastatic breast cancer, or
control. The numbers of CA microsatellite repeats were
determined for each individual, and the results were
interpreted collectively for each group.
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2.3. Statistical analysis
An analysis of data normality (including age, survival
time, number of lymph nodes removed, and number of CA
repeats) was performed graphically and by using a Shapiro–
Wilk test. All variables, except for survival time, showed a
normal distribution. To represent the descriptive statistics,
numbers and percentages were used for the categorical
variables. The medians and standard deviations were
used as measurement variables depending on the normal
distribution. A Kruskal–Wallis test was used to compare
CA repeat frequencies among the control, metastatic, and
nonmetastatic groups. A Bonferroni-corrected Mann–
Whitney test was referenced in the post hoc pairwise
comparisons. A chi-square test was used to investigate the
differences between the categorical variables (pathological
grade, histological group, receptors, etc.) in the metastatic
group. Student’s t-test was used to examine the differences
due to the presence of metastases on survival time. All
statistical analyses and calculations were performed using
MS Excel 2003 and SPSS 15.0 (SPSS Inc., Chicago, IL,
USA). P < 0.05 was considered statistically significant.
3. Results
The distributions of the number of CA repeats in the
control, metastatic, and nonmetastatic groups are shown in
Figure 1. Differences in the number of CA repeats among
the groups were determined using Bonferroni-corrected
post hoc pairwise comparisons (χ2 = 31.162; P < 0.001).
We observed that the median number of CA repeats in
the control group was significantly greater than that in the
nonmetastatic group (Z = 4.757, P < 0.001; Z = 5.180, P <
0.001), but this was not significantly different with respect
to the metastatic group (Z = 0.601; P = 0.548). Additionally,
the median number of CA repeats in metastatic patients
was significantly higher than in nonmetastatic patients
(Z = 5.180; P < 0.001). When sorted by the median value
for CA repeats, the smallest CA repeat number belonged
to the nonmetastatic group, and the highest median was
observed in the metastatic group. The medians of the
control and metastatic groups were similar.

The tumor grade and phase were considered as they
correlated with the median number of CA repeats, and the
results are shown in Tables 1 and 2. The median number
of CA repeats was statistically similar according to their
grade (Z = 1.205; P = 0.246; Table 1). However, the median
of at least one phase was different from those of the other
phases (c2 = 17.264; P < 0.001; Table 2). To determine
which phase caused this difference, the Bonferronicorrected Mann–Whitney test was employed. Accordingly,
there was no statistically significant difference between
the medians of Phase 1 and Phase 2 (2A + 2B) patients
(Z = 1.625; P = 0.126). However, there was a statistically
significant difference between the median values of Phase
1 and Phase 3 (3A + 3B) patients (Z = 3.757; P < 0.001).
Moreover, the difference between the median values of
Phase 2 (2A + 2B) and Phase 3 (3A + 3B) was statistically
significant (Z = 2.994; P = 0.003). When the patients were
ranked according to the values of their (CA)n medians,
the smallest median belonged to Phase 1 patients, and the
highest median belonged to Phase 3 (3A + 3B) patients.
Next, we evaluated the number of CA repeats in the
estrogen receptor (ER), progesterone receptor (PR),
c-erbB2 receptor (human epidermal growth factor
receptor 2, HER2, also known as Neu), and ER + PR groups
individually. However, we noted no significant differences
with respect to these groups (respectively, Z = 1.944, P =
0.061; Z = 1.394, P = 0.193; Z = 0.549, P = 0.549; Z = 1.944,
P = 0.061; data not shown).
4. Discussion
We investigated the CA repeat length in the promoter
region of the ADAMTS9 gene to uncover a potential
association with breast cancer lymphatic metastasis. With
regard to the median numbers of CA repeats, we observed
no significant difference between the metastatic group
and the control group (Z = 0.601; P = 0.548). However,
the median number of CA repeats was significantly higher
in the control group when compared to the nonmetastatic
group (Z = 4.757; P < 0.001). These results suggest that
expansion in the number of CA repeats from normal repeats
Nonmetastatic

CA-21
37%

CA-19
17%
CA-20
46%

CA-19
16%
CA-21
47%

CA-20
37%

CA-18
33%
CA-17
67%

Figure 1. Circle chart representations of the number of CA repeats in each group.
Distribution of the number of CA repeats in control, in metastatic, and in nonmetastatic
groups. CA: cytosine-adenine dinucleotide. Number following dash indicates the
number of CA repeats in the ADAMTS9 promoter region.
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Table 1. (CA)n median values after analysis with respect to grade.
Grade

n

%

Median

CAG

Grade 1

14

45.2

18.5

2.3

Grades 2 + 3

17

54.8

20.0

4.0

Z / χ2

P

Z = 1.205

0.246

Table 2. (CA)n median values after analysis with respect to phase.
Phase

n

%

Median

CAG

Phase 1

7

22.6

17.0

1.0

Phase 2 (2A + 2B)

11

35.5

19.0

3.0

Phase 3 (3A + 3B)

13

41.9

21.0

1.0

may not affect tumor formation but may potentially reduce
the risk of metastasis in the tumor microenvironment.
We hypothesize that CA repeat contraction in the
microsatellites located in the ADAMTS9 promoter
may block RNA polymerase binding to the ADAMTS9
promoter. If this scenario is correct, cancer-related gene
expression, such as that of ADAMTS9, in tumors would
decrease (15,16), and lower matrix metalloproteinase
activity would translate into a reduced ability to invade
lymphatic vessels and metastasize. Porter et al. reported
that the expression of ADAMTS9 in breast cancer tissues
was down-regulated with respect to noncancerous breast
tissues and uncovered a potential association between
ADAMTS9 and breast cancer (17). Since ADAMTS9 maps
to regions known to be frequently deleted in breast cancer
and other malignancies (8,9,13,16), we await with interest
further observations regarding the possible implication
of CA repeat polymorphisms in tumorigenesis and
metastasis.
Similar studies were previously performed with the
MMP-9 (12), IGF-1 (13), and PARP-1 (14) genes, which
are in the same gene family as or have similar functions
to ADAMTS9. Zaremba et al. studied the effects of
PARP-1 activity in 118 cancer patients and 56 healthy
control patients. Variations in PARP-1 activity caused by
polymorphisms in the composition of the PARP-1 gene
or protein were thought to affect the patients’ response
to cancer therapy. Although both PARP-1 activity and
protein expression were similar in the control and cancer
patient groups, the number of CA repeats in the PARP1 promoter was found to be shorter in the patient group
compared to the control group (14). In the study by
Javadi et al., the number of CA dinucleotide repeats in the
IGF-1 promoter was determined for 215 female patients
diagnosed with breast cancer. Although the alleles and
genotypes were similar in both the 215 cancer patients and
the 224 matched controls with or without a family history
of breast cancer (first- and second-degree relatives), and
the number of CA repeats was approximately 19, it was
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Z / χ2
χ2 = 17.264

P
<0.001

observed that the risk of breast cancer increased with
the expansion of 2 CA repeats and decreased with the
contraction of 2 CA repeats (13). Shimajiri et al. studied
CA repeat length in the promoter region of the MMP-9
gene in esophageal cancer cell lines (12). In their study,
the CA repeat length was thought to regulate MMP9 gene transcription and enzymatic function. MMP-9
plays an important role in tumor growth, invasion, and
metastasis. It is thought that a decrease in the number
of CA repeats induces down-regulation of the MMP-9
transcription (12). In all of these aforementioned studies,
the investigated genes were similar to the ADAMTS9 gene
with regard to their association with cancer and metastasis.
Moreover, they resemble ADAMTS9 in their cysteinerich structures, matrix metalloproteinase properties,
extracellular thrombospondin motifs, and aggrecanase and
antiangiogenic activities. Our finding that a lower median
value for the number of CA repeats, which was associated
with low metastasis risk, was detected in the ADAMTS9
promoter of the nonmetastatic group compared to the
other groups is consistent with previous findings.
The axillary lymph nodes are the major drainage area
for the breast, and a negative correlation between axillary
metastasis and prognosis has been shown by Nemoto et
al. (18), Haffty et al. (19), and Fisher et al. (20). In our
study, metastatic axillary lymph nodes were present in
61.29% of patients (n = 19). The median number of CA
repeats in the control and metastatic lymph node groups
was significantly greater than in the nonmetastatic lymph
node group (Z = 4.757; P < 0.001). This result suggests a
potential relationship between the number of CA repeats
and lymph node metastasis.
The findings by Hanahan and Weinberg are in
accordance with the findings of the present study. In their
study, the metastatic tumor cell itself had evolved over
time and reacquired the ability to metastasize, which
was considered a result of extracellular matrix degrading
protease (e.g., MMP-9) (21). Similarly, we interpret the
similar number of CA repeats in both the metastatic and
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control groups as an adaptation of the tumor cells to the
microenvironment.
The primary factor affecting the prognosis of breast
cancer is the status of metastasis (22). The most critical
step for both regional and distant metastases is to traverse
the extracellular matrix surrounding the tumor. Several
matrix metalloproteinases are known to contribute to
the invasion and traversal of the extracellular matrix
in metastatic spreading. Together with ADAMS, the
ADAMTS proteinases have been shown to play a role
in cancer development and progression (16). Because
ADAMTS9 is a matrix metalloproteinase, ADAMTS9
gene expression may be related to tumor progression and
metastatic spreading.
Studies in the field of prognostic biomarkers that
attempt to predict the course of disease have gained
considerable importance due to their indisputable value
in cancer surveillance. Genetic factors are involved in
carcinogenesis and are known to influence prognosis
(5). For this purpose, the MMP, ADAM, and ADAMTS
gene families are of particular interest for further study.
These gene families have been found to promote tumor
formation, propagation, metastasis, and angiogenesis in
various cancer types (23,24).
The median value for the number of CA repeats in the
control group was similar to that of the metastatic group,
but the nonmetastatic group had a significantly lower
median value. Hence, a potential relationship between
the number of CA repeats in the ADAMTS9 promoter
and lymphatic metastasis of breast cancer may exist. We
hypothesized that a CA repeat contraction may inhibit
the tumor invasion metastasis cascade due to ineffective
A
Chromosome 3

Genes

B

binding of RNA polymerase to the target region on the
promoter and the subsequent decrease in ADAMTS9
expression. As a result, ADAMTS9 cannot carry out its
matrix metalloproteinase activity and fails to perform
lymphatic vessel invasion, and thus prevents metastasis
by this mechanism. One report suggested that shortened
microsatellite CA sequences down-regulate promoter
activity of the MMP-9 gene (12). Genetic mutations in
CA microsatellites that are located in the gene’s promoter,
or increasing cytosine methylation of the promoter, may
cause promoter activity augmentation. It is considered
that a scarcity in the number of CA repeats induces downregulation of the promoter region of MMP and MMPrelated genes, such as ADAMTS9, and this down-regulation
stimulates a couple of oncogenic mechanisms that cause
an increased risk of cancer incidence. Another explanation
is cytosine expansion (21). Cytosine expansion may affect
the transcription factors binding to the promoter. The
metastatic tumor cell reacquiring the ability to metastasize
was considered a result of CA repeat expansion. Vilar and
Gruber investigated the effect of microsatellite instability
in colorectal cancers (25). Microsatellites in the human
genome are formed by 2 or more nucleotide repeats and
are used as molecular markers for mismatch repair system
defects. By coming together, in particular (CA)n and
(CAG)n sequences accumulate mutations and inhibit the
binding function of DNA polymerase to DNA effectively
in the synthesis (25). A limitation of our study was the lack
of expression analysis in tumor samples. An increasing
number of ADAMTS studies (26
–28) and further
experiments will elucidate the ADAMTS9 gene (Figure 2)
Promoter Region

-2000

+33

CADPS
PRICKLE2
3p14.3 region
Centromere

MAGI1

CA ATG
……….TTGAAATTATCTTGAAATTCTATCTTCCTGAGGGCTGGT
repea
TAAAGAAAAGGCGCCACTGAACCACCCAAGATTGAACAATT
ts
CACACACACACACACACACACACACACACACACACACACGA
(CA)

ADAMTS9
C

UBE1C

D

NFKB

NFKB PEA3/NFAT

Sp1 NFKB

AGGTGTAGCTTGAAGCGCCTGCTTTCAGTCTTTCCCAGTCTTT
C C A A G C A T C T C T C A … …
CGCCGCAGCCAAGGAGGGCAGGAGGGAGGGGGGTGGGGGC
AGCGGAGGGAGGGGTGGGAAGCACCATGCAGTTTGTATCCT
GGGCCACACTGCTAACGCTCCTGGTGCGGGAC ………

Figure 2. Chromosomal location and promoter of the ADAMTS9 gene. A) Illustration of the ADAMTS9 gene on 3p14.3. B) Binding
sites of putative transcription factors (NF-κB, NFAT, Sp1) on the ADAMTS9 gene. Potential binding site, e.g. RunX, is also involved
in the ADAMTS9 promoter. C) Partial sequence of the ADAMTS9 gene; promoter region has 19 CA repeats located around –1489
(red); green capital letters show exon 1. Transcription start site (ATG) is in red capital letters and underlined. D) ADAMTS9 protein
domains. T: thrombospondin (TSP); S: signal peptide. ADAMTS9 has 15 TSP domains.

675

BOZER et al. / Turk J Med Sci
architecture, function, and promoter anatomy in cancer
progression. Recently, Li et al. demonstrated that CA
repeats within the endothelin-converting enzyme-1
(ECE-1c) gene promoter are highly polymorphic and
harbor transcriptional start sites and CA repeat length,
indicating shifted allelic frequency distributions. These
data indicate that genomic repeat composition constitutes
a novel core promoter element and affects transcriptional
start site determination (29).
In conclusion, we found that both the control and
metastatic groups had similar median numbers of CA
repeats, but the higher median value of the number
of CA repeats was significant compared to that of the
nonmetastatic group. Therefore, the ADAMTS9 gene may
renew itself by adapting to the host cell and imparting
the tumor cell with the ability to metastasize through CA
repeat composition. These data should also encourage
the study of ADAMTS’ role in breast cancer pathogenesis

(30–34) as a potential novel target for rational therapeutic
strategies.
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